The global diabetes drugs market derives growth from advancements in drug delivery systems. According to a report published by Fortune Business Insights, titled "Diabetes Drugs: Global Market Analysis, Insights and Forecast, 2019-2026," the market was valued at US$ 48,753.1 Mn in 2018. Fortune Business Insights has predicted that the market will be valued at US$ 78,261.7 Mn by the end of 2026, thereby exhibiting a CAGR of 6.1%.
The other highlights of the report include:
? Targeted analysis of the impact of COVID-19 on the market;
? Detailed study of the factors, trends, and constraints shaping the market;
? Careful evaluation of the regional dynamics influencing the market; and
? Thorough profiling and examination of the key market players and their strategies.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetes-drugs-market-100570
Availability of Low-Cost Insulin to Boost the Market
Insulin is one of the most widely used drugs for the treatment of diabetes. The exceptional properties and clinical efficacy of insulin have led to a rising uptake. Despite high efficacy, the cost associated with insulin has been a barrier towards the growth of insulin.
Considering this factor, many companies are exploring potential ways to the reduced cost associated with insulin for management of diabetes. In 2019, Eli Lilly and Company, launched a new insulin drug, that was almost half the price of its previous brands. Eli Lilly announced the low-cost insulin 'Lispro', a product that was priced significantly less than its previous Humalog injection.
Fortune Business Insights' latest report on the global diabetes drugs market is an encompassment of such product advancements. The report gauges the impact of product innovations, similar to Lispro, on the global market.
The global economy is in absolute turmoil because of the COVID-19 pandemic outbreak. Some industries remain largely unaffected by the outbreak, some are thriving, but most are in doldrums. Although the healthcare industry is flourishing, certain markets within the industry are experiencing staggered growth. Wading through these troubled times is a difficult task and Fortune Business Insights(TM) aims at equipping your business with the most comprehensive market insights, collated and analyzed by our expert and experienced research team.
Click here to get the short-term and long-term impact of COVID-19 on this market.
Please visit: https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570
Encouraged by High Demand, Glenmark Extends Insulin Sales in India
In 2019, Glenmark Pharmaceuticals announced that it plans to bring its Remogliflozin Etabonate to India. The high demand for diabetes drugs in India has influenced Glenmark's latest move. Additionally, a huge diabetic patient pool has also contributed to the high demand for diabetes drugs in India.
Such competitor moves have aided the growth of the global diabetes drugs market. The report includes company activities, similar to the aforementioned case. The report includes detailed analysis of company activities such as takeovers, mergers and acquisitions, agreements, and investment.
Increasing Drug Approvals Have a Positive Impact on Overall Market
The high prevalence of diabetes on a global scale has paved way for several clinical trials. Increasing drug approvals have aided the growth of the global diabetes drugs market. Novo Nordisk's 2018 launch of Ozempic and Fiasp is a perfect example of the aforementioned case. Additionally, the company received approval from the Food and Drug Administration and this has aided the business expansion of Novo Nordisk. The company's latest drug approvals will bode well for the global diabetes market and is likely to enable growth of the market in the coming years.
Fortune Business Insights has summarized the impact of several companies on the global diabetes drugs market. Furthermore, Fortune Business Insights has labelled out leading companies that have made significant contributions to the growth of the global diabetes drugs market.
Quick Buy - Diabetes Drugs Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100570
Some of the leading companies that are operating in the global diabetes drugs market are
-- Novo Nordisk A/S
-- Merck & Co., Inc.
-- Eli Lilly and Company
-- Takeda Pharmaceutical Company Limited
-- Boehringer Ingelheim International GmbH
-- Novartis AG
-- Johnson & Johnson Services, Inc.
-- Bayer AG
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/diabetes-drugs-market-100570
Diabetes Drugs Market Segmentation:
By Drug Class
? DPP-4 Inhibitors
? GLP-1 Receptor Agonists
? SGLT2 Inhibitors
By Diabetes Type
? Type 1
? Type 2
By Route of Administration
By Distribution Channel
? Online pharmacies
? Hospital Pharmacies
? Retail Pharmacies
? North America (U.S. and Canada)
? Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
? Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
? Latin America (Brazil, Mexico, and Rest of Latin America)
? Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/diabetes-drugs-market-100570
Have a Look at Related Reports:
Diabetes Treatment Devices Market Share and Global Trend By Product (Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Insulin Syringes, Others), By Distribution Channel (Institutional Sales (Hospitals, Clinics), Retail Sales (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)) & Geography Forecast till 2026
Diabetes Devices Market Share and Global Trend By Product (Monitoring Devices, Treatment Devices), By Distribution Channel (Institutional Sales, Retail Sales) and Geography Forecast till 2026
Human Insulin Market Share & Industry Analysis, By Type (Analogue Insulin, Traditional Human Insulin), By Diabetes Type (Type 1, Type 2), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), and Regional Forecast, 2019-2026
Blood Glucose Monitoring Systems Market Share & Industry Analysis, By Device (Continuous Blood Glucose Monitoring Systems, Self-monitoring of Blood Glucose Systems), By Type (Invasive, Non-invasive), By Modality (Wearable, Non-wearable), By Distribution Channel (Institutional Sales, Retail Sales), and Regional Forecast 2019-2026
Insulin Pens Market Share and Global Trend By Product Type (Disposable, Reusable), By Application (Type 1 Diabetes, Type 2 Diabetes), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, Diabetes Clinics), Geography Forecast till 2026
Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights(TM) Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune - 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Fortune Business Insights(TM)
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/diabetes-drugs-market-9136